IsoRay, Inc. (NYSEMKT:ISR) reported 11% revenue increase during 2013 Quarter. According to the reports the company witnessed revenue earnings growth from the addition of new facilities utilizing Cesium-131, earnings from continued accrual of patients under several active studies. The company also announced FDA has cleared Liquid Cesium-131. Liquid Cesium-131 will help company’s revenue increase by promoting IsoRay’s treatment along with GliaSite® balloon catheter as an alternative for treating recurring and complicated cancers located throughout the body. The company’s financial results continue to be impacted by Affordable Care Act and to ensure the company makes gain in the future sales IsoRay, Inc continues will invest in R&D data protocols. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $1.10 moved to $3.04 on last trade day and at the end of the day closed at $2.55. Company price to sales ratio in past twelve months was calculated as 21.30 and price to cash ratio as 22.27. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 207.23%.
Zacks reissued their neutral rating on shares of WellPoint (NYSE:WLP)in a research report sent to investors on Friday morning,StockRatingsNetwork.com reports. The firm currently has a $98.00 price target on the stockWellPoint Inc (NYSE:WLP) shares advanced 1.37% in last trading session and ended the day on $99.05. WLP return on equity ratio is recorded as 19.60% and its return on assets is 8.10%. WellPoint Inc (NYSE:WLP) yearly performance is 56.85%.
Albany Molecular Research (Nasdaq:AMRI) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins.Albany Molecular Research, Inc. (NASDAQ:AMRI) shares moved up 1.18% in last trading session and was closed at $19.78, while trading in range of $19.39-$20.55. Albany Molecular Research, Inc. (NASDAQ:AMRI) year to date performance is 96.23%.
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA based molecular diagnostics has shared detailed plans about its product pipeline based on its proprietary technology in a news release.Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) weekly performance is 5.75%. On last trading day company shares ended up $6.44. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) distance from 50-day simple moving average is 56.11%. Analysts mean target price for the company is $3.50.
Leave a Reply